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The population of the United States is aging,
and an ever-increasing number of Americans
are afﬂicted with neurodegenerative diseases.
Neurodegenerative diseases result from the
gradual and progressive loss of neural cells,
leading to nervous system dysfunction.
According to the National Institute of
Neurological Disorders and Stroke, there are
more than 600 neurologic disorders, with
approximately 50 million Americans affected
each year.
These diseases cost the U.S. economy bil-
lions of dollars each year in direct health care
costs and lost opportunities; it is estimated that
$100 billion per year is spent on Alzheimer dis-
ease (AD) alone (Meek et al. 1998). In addition
to the ﬁnancial costs, there is an immense emo-
tional burden on patients and their caregivers.
As the number of elderly citizens increases,
these costs to society also will increase.
Until recently, most concerns about envi-
ronmental agents have centered on their
potential for causing cancer. Cancer and
neurodegeneration represent opposite ends of a
spectrum: whereas cancer is an uncontrolled
proliferation of cells, neurodegeneration is the
result of the death of cells, whether due to
direct cell death by necrosis or the delayed
process of apoptosis. Attention is now being
focused on environmental agents’ potential for
damaging the developing and mature nervous
system, resulting in neurodegenerative diseases.
Known risk factors for neurodegenerative
disease include certain genetic polymorphisms
and increasing age. Other possible causes may
include gender, poor education, endocrine con-
ditions, oxidative stress, inﬂammation, stroke,
hypertension, diabetes, smoking, head trauma,
depression, infection, tumors, vitamin deﬁcien-
cies, immune and metabolic conditions, and
chemical exposure. Because the pathogenesis of
many of these diseases remains unknown, we
must consider the role of environmental factors
in these diseases.
In this review we examine the human
evidence for environmental etiologies for
some diagnosed neurodegenerative diseases.
Epidemiologic literature, not case studies or
experimental animal research, was searched
for relevance to an association between
neurodegenerative diseases and environmen-
tal agents. We briefly review genetics and
lifestyle habits (e.g., smoking, coffee, alcohol)
but not other potential risk factors such as age
at onset, socioeconomic status, gender, eth-
nicity, and education. Although it is acknowl-
edged that the etiology of neurodegenerative
diseases is often multifactorial (particularly
gene–environment interactions), the purpose
of this review is to examine the extent of the
available epidemiologic literature solely on
environmental agents.
Study Type Selection
The greatest assurance for causality comes
when the exposure to the environmental agent
can be determined before the outcome.
Because of the nature and variety of neuro-
degenerative diseases, the vast majority of
cases are observed in the elderly population,
yet the exposure could have occurred years or
decades before the resulting effect. This long
latency period makes it extremely difﬁcult to
track exposures before the outcome in a longi-
tudinal fashion. A few groups have conducted
studies of this type (Abbott et al. 2003; Baldi
et al. 2003b; Hernan et al. 2001; Lindsay et al.
2002; Petrovitch et al. 2002; Preux et al. 2000;
Rondeau et al. 2000; Tyas et al. 2001).
Because of these major constraints, many
investigators have used a case–control study
design that examines cases after diagnosis. The
major limitation of this type of study is recall
bias (see “Bias”). Ecologic studies are another
type of study, with the major limitation being
the inability to characterize exposure data to
individuals (see “Exposure Deﬁnition”).
Disease Deﬁnition
Precise determinations of neurodegenerative
disease can be elusive, although for approxi-
mately 80% of cases, a diagnosis made by a
clinician is confirmed postmortem (Mok
et al. 2004). For many cases, a confident
diagnosis can be made only during an exami-
nation of brain tissue after death. Because
autopsies are not always conducted, when
using mortality data such as death records,
there are obvious problems if the neurologic
disease in question is not listed as a primary
or secondary cause of death (Ritz and Yu
2000). Most studies focus on symptoms
ascertained during life, and many of the crite-
ria used to deﬁne neurologic disease are left to
a certain extent to subjectivity, with inevitable
associated misclassiﬁcation of disease.
Also, there are difficulties associated in
accurately differentiating one neurologic dis-
ease from another, particularly since many
conditions may co-exist. For example Drayer
et al. (1986) measured “Parkinson plus syn-
drome,” which was deﬁned as Parkinson dis-
ease (PD) and multiple system atrophy (MSA),
or PD and progressive supranuclear palsy
(PSP). There is also co-morbidity of vascular
conditions such as stroke or coronary heart dis-
ease. To complicate matters further, diagnostic
criteria have changed or evolved over time. For
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recently as 1998 (Wenning et al. 2004).
One solution to the problems associated
with diagnosing neurodegenerative diseases
would be to measure neurologic symptoms
individually and early, before clinical diagno-
sis. Formal neuropsychologic tests can pro-
vide some objective support. Several lines of
evidence have been published with this focus
(Baldi et al. 2001; Engel et al. 2001; Farahat
et al. 2003; Kamel and Hoppin 2004; Kamel
et al. 2003; Pilkington et al. 2001). However,
there may be some uncertainty with linking
early subtle effects with clinical diagnosis. For
this reason, we examine in this review only
those studies where there was deﬁnitive clini-
cal diagnosis for neurodegenerative disease.
Exposure Deﬁnition
A number of studies have examined the
relationship between exposure to environ-
mental agents and neurologic outcomes.
Many studies involve a plethora of individual
agents as a mixture, so it is understandable
that some have not found an association for
neurologic outcomes using a broad exposure
definition. Similarly, the grouping of pesti-
cides as an exposure category may be entirely
too large. Many researchers have attempted to
subdivide this class of chemicals into insecti-
cides, herbicides, and fungicides, but even
then a large number of substances could be
classiﬁed within these clusters, and it remains
difficult to tease out the associated environ-
mental agent with the adverse outcome. For
example, Baldi et al. (2003b) note the lack of
information on speciﬁc pesticides because of
trade secrets, although they could surmise the
pesticides most often used in vineyards would
be fungicides.
Accurate exposure assessment may be dif-
ﬁcult to perform because of the retrospective
aspect of case–control studies (see “Bias”).
Also, assigning exposure categories may result
in misclassification for ecologic studies
(Gauthier et al. 2001; Ritz and Yu 2000) and
when proxy respondents are used (Gauthier
et al. 2001). There is often a lack of
dose–response data, and similarly, the inten-
sity of exposure may be missed. In environ-
mental exposure data, there may be a peak
exposure not captured in averaged exposure
data, or there may be an accumulation of low-
level exposure that may be below the detection
limit. For biomonitoring data, nonpersistent
exposures will be difficult to capture with
accuracy, and the organ or tissue assessed may
or may not be where the chemical is deposited
or where it has an effect. Finally, if for some
exposures there is an earlier critical window of
exposure that sets the stage for later neurologic
degeneration, a focus on later exposure history
may not capture early developmentally rele-
vant exposures.
Power
To ﬁnd statistically signiﬁcant results, inves-
tigators must have a sufficiently large study
sample, or once the data are stratified the
results will not be very telling. Likely this is
why many investigators publish results on
groups of chemicals (i.e., pesticides) rather
than on speciﬁc chemicals, or on diagnosable
diseases rather than on individual symptoms.
Therefore, it is not surprising that little evi-
dence exists to support an association
between PD and specific pesticides (Engel
et al. 2001; Hertzman et al. 1994). One
study in particular did ﬁnd an association for
paraquat and PD (Liou et al. 1997), and
another found an association between
organochlorines and alkylated phosphates
and PD (Seidler et al. 1996). However, the
number of studies examining specific pesti-
cides resulting in statistically signiﬁcant con-
clusions is limited.
Additionally, many of the case–control
studies use small numbers of study partici-
pants, particularly those studies measuring
biomarkers of exposure (Bergomi et al. 2002;
Drayer et al. 1986; Felmus et al. 1976;
Fleming et al. 1994; Gellein et al. 2003;
Kapaki et al. 1989; Kasarskis et al. 1995;
Miyata et al. 1983; Moriwaka et al. 1993;
O’Mahony et al. 1995; Rajput et al. 1986;
Sood et al. 1990; Stober et al. 1983; Vinceti
et al. 2002; Yasui et al. 1991a, 1991b, 1993).
This limits the amount of power to detect a
statistically significant association. Also,
although not discussed in this review, the
increasing focus on gene–environment inter-
actions will have a major impact on the
results because of the need to stratify results
across genotype as well as chemical type.
Bias
Closely related to exposure assessment, a
major difﬁculty for case–control studies gener-
ally is recall bias. Because the exposures tend
to occur much earlier than the diagnosed out-
come, the individual is asked to remember
potential exposures over a long period; this is
exacerbated for neurological diseases because
the outcomes in question also tend to affect
memory. However, those individuals with
symptoms may overreport exposures because
of the desire to determine a cause for their
condition.
Selection bias may occur if those partici-
pating in the study are healthier than those
who do not participate. This is known as the
“healthy worker effect” because many occupa-
tional studies contain only those employees
who have remained healthy and able to retain
their job. For nonoccupational studies, those
with more severe neurodegenerative diseases
may participate to a lesser degree because of
their reduced ability to communicate and
travel to study centers.
Confounders
As mentioned above, other risk factors for
neurodegenerative disease may include gender,
endocrine conditions, oxidative stress, infec-
tion and inflammation, nutrition, vascular
conditions, depression, head trauma, tumors,
and level of education. Ethnicity and culture
may also have implications and provide
insights into the etiology of some diseases
(Marder et al. 1998). In particular, smoking
and caffeine and alcohol consumption have
been postulated to have an association with
neurodegenerative diseases.
Although the protective effect of smoking
on PD is well known (Allam et al. 2004; Quik
2004; Ross and Petrovitch 2001), there is con-
flicting epidemiologic evidence regarding an
association between smoking and risk of AD
(Almeida et al. 2002; Letenneur et al. 2004).
There is much less evidence for an association
between smoking and parkinsonian syndromes,
but one study showed a protective effect for
MSA but not for PSP (Vanacore et al. 2000).
Similarly, caffeine consumption has gener-
ally been shown to be protective against the
development of PD (Ross and Petrovitch
2001), although there is much less consistent
information for an association with AD
(Lindsay et al. 2002; Tyas et al. 2001). There
is mixed evidence for a protective effect of
alcohol and PD (Behari et al. 2001; Benedetti
et al. 2000; Checkoway et al. 2002; Fall et al.
1999; Kuopio et al. 1999; Liou et al. 1997;
Morano et al. 1994; Paganini-Hill 2001;
Wang et al. 1993) and less for alcohol and AD
(Letenneur et al. 2004; Tyas 2001).
Alzheimer Disease
Alzheimer disease is perhaps the prototypical
degenerative disease affecting the central ner-
vous system. AD is a chronic progressive
disease characterized by memory loss and
deﬁcits in one or more of the following cogni-
tive domains: aphasia (language disturbance),
agnosia (failure to recognize people or objects
in presence of intact sensory function), apraxia
(inability to perform motor acts in presence of
intact motor system), or executive function
(plan, organize, sequence actions, or form
abstractions). In addition, these deﬁcits must
be severe enough to interfere with daily life or
work, and they must represent a significant
decline from an earlier level of function. It is
estimated that about four million Americans
are currently diagnosed with AD. The preva-
lence rate is about 7% for individuals aged
65 or more, with the risk doubling every
5 years after age 65 (McCullagh et al. 2001;
McDowell 2001).
Although most cases of AD are thought to
be sporadic, there are at least four well-known
risk factors for AD: increasing age, familial
association, Down syndrome, and the apolipo-
protein E4 allele (Cedazo-Mínguez and
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et al. 2004; Rubinsztein and Easton 2000;
Weisgraber and Mahley 1996). Some exam-
ples of the association betwen exposure to
environmental agents and AD are described
brieﬂy below.
Heavy metals are well-recognized environ-
mental agents that affect brain development,
leading to life-long impairment. Several epi-
demiologic studies have examined the possible
link between aluminum (Al) and AD, with
conflicting results. One study found Al in
antiperspirants to be significantly associated
with AD (Graves et al. 1990), but others
showed no association for Al in antiperspirants
(Lindsay et al. 2002) or in antacids (Broe et al.
1990; Graves et al. 1990; Lindsay et al. 2002;
Tyas et al. 2001). Studies examining occupa-
tional exposures of Al found slightly elevated
but nonsignificant risk (Graves et al. 1998;
Salib and Hillier 1996) or no association (Gun
et al. 1997). Also, no association was observed
for Al in bone and AD (O’Mahony et al.
1995). One reason for this discrepancy in
occupational studies is the inaccurate exposure
assessment based on job description and rated
for exposure to metals (Graves et al. 1998).
Furthermore, these comparisons may not
be appropriate because of the different types
of exposures, for example, dermal, oral,
and inhalation.
The ﬁndings for an association between Al
in drinking water and AD are also incon-
clusive. Two studies demonstrated statistically
significant results (McLachlan et al. 1996;
Rondeau et al. 2000), although the latter did
not ﬁnd a dose–response relationship. Others
have found no association (Forster et al. 1995;
Martyn et al. 1997). Because of this variability,
some researchers are now attempting to explore
whether speciation of Al plays any role in cau-
sation of AD. For example, Gauthier et al.
(2000) found an association with monomeric
organic Al in drinking water and AD but not
with other forms of Al.
Metals other than Al have also been stud-
ied for the relationship with AD but to a much
lesser extent. No association was observed for
occupational exposure to lead or mercury
(Gun et al. 1997), mercury from dental amal-
gams (Saxe et al. 1999), or increased mercury
in the pituitary gland of AD cases versus con-
trols (Cornett et al. 1998a). However, a non-
significant elevation of mercury in the brain
was associated with AD (Cornett et al. 1998b).
Similarly, a statisticially signiﬁcant association
was observed between AD and an elevation of
iron in the brain (Cornett et al. 1998b) but not
in the pituitary gland (Cornett et al. 1998a),
although these studies may have suffered from
low power. Related to the storage of iron, an
increase of the protein ferritin was found to be
higher in the cerebral spinal ﬂuid of patients
with AD than that of controls (Kuiper et al.
1994). A statisticially significant association
was found between AD and an elevation of
zinc in the brain (Cornett et al. 1998b) but not
for concentrations of zinc in hair and serum
(Shore et al. 1984) or pituitary gland (Cornett
et al. 1998a), although these studies may have
suffered from low power. No association was
observed for hair and serum concentration of
copper or magnesium and AD (Shore et al.
1984). An association was observed between
AD and increased selenium levels in the brain
(Cornett et al. 1998b) but not in the pituitary
gland (Cornett et al. 1998a).
The neurologic effect of some pesticides
(especially organophosphates and carbamates)
on their intended targets is known, and the
evidence is growing for the unintended conse-
quences on humans. A signiﬁcant association
was observed between occupational exposure
to pesticides in general and AD (Baldi et al.
2003b), and statistical significant risk was
observed for fumigants and defoliants and
AD (Tyas et al. 2001). Others have not found
an association for occupational (Baldi et al.
2003b; Gun et al. 1997; Tyas et al. 2001) or
residential exposure to pesticides and AD
(Gauthier et al. 2001). Fleming et al. (1994)
examined the biologic burden of pesticides in
AD cases and found an association between
pesticides measured in the brain and AD.
Electromagnetic ﬁelds (EMFs) have been
suspected as a causal factor for the development
of AD. Sobel et al. (1996) found a strong asso-
ciation for EMFs and AD, with an increased
risk for males compared with females.
Feychting et al. (1998) found a strong but non-
significant association with AD. A dose–
response trend was observed for both outcomes.
However, Graves et al. (1999) observed no
association between EMF exposure and AD.
The few studies examining solvent expo-
sure and the development of AD are contra-
dictory. One study using job description as
proxy for exposure assessment found a non-
signiﬁcant but suggestive association (Graves
et al. 1998), yet other studies (Gun et al.
1997; Tyas et al. 2001) and a meta-analysis
found no association (Graves et al. 1991).
Parkinson Disease
Parkinson disease is unique from AD in that it
is characterized by abnormalities of motor con-
trol, as opposed to intellectual and personality
changes. PD is characterized by resting
tremors, bradykinesia (slowness of voluntary
movement), rigidity, and a loss of postural
reﬂexes. Patients with PD typically have a ﬂat,
expressionless face and walk with a stooped gait
characterized by small steps. Many patients
also experience severe depression.
The lifetime risk for PD is estimated to be
2 and 1.3% for men and women, respectively,
and between 3.7 and 4.4% for “parkinson-
ism,” a term used to characterize other clinical
conditions characterized by akinesia and rigid-
ity that do not meet clinical or pathologic crite-
ria for idiopathic PD (Elbaz et al. 2002).
Although a number of genetic polymorphisms
are linked to PD (Checkoway et al. 1998), it is
likely that the majority of cases of PD are not
inherited but related to environmental factors.
This is supported by a genetic study of twins
by Tanner et al. (1999), who observed that
monozygotic–dizygotic concordance rates are
indistinguishable, implying a lack of genetic
influence and a strong probability of an
environmental inﬂuence. Examples of environ-
mental risk factors for PD are discussed below.
Substantial numbers of epidemiologic
studies have found positive associations
between PD and exposure to pesticides (Abbott
et al. 2003; Baldi et al. 2003a, 2003b; Fall et al.
1999; Herishanu et al. 2001; Hertzman et al.
1994; Liou et al. 1997; Petrovitch et al. 2002;
Ritz and Yu 2000; Seidler et al. 1996), herbi-
cides (Butterﬁeld et al. 1993; Gorell et al. 1998;
Semchuk et al. 1992, 1993), insecticides
(Butterﬁeld et al. 1993; Gorell et al. 1998), and
for residence in a fumigated home (Butterﬁeld
et al. 1993). Similarly, Fleming et al. (1994)
found increased levels of pesticides in the brains
of PD cases versus controls.
There are also a number of studies that
have shown no association between PD and
pesticide exposure (Behari et al. 2001; Koller
et al. 1990; Kuopio et al. 1999; McCann et al.
1998; Smargiassi et al. 1998; Stern et al.
1991), herbicide exposure (McCann et al.
1998; Smargiassi et al. 1998), and fungicide
exposure (Gorell et al. 1998). Some studies use
a broad exposure deﬁnition for pesticides, as
mentioned above.
Farming occupation and farm residence are
related to pesticide exposure. A signiﬁcant asso-
ciation was found for PD and farmworkers
(Gorell et al. 1998; Ho et al. 1989; Wechsler
et al. 1991) and orchard workers (Hertzman
et al. 1990). However, these positive ﬁndings
have not been replicated by other investigators
examining farming (Baldi et al. 2003b; Behari
et al. 2001; Chan et al. 1998; Engel et al. 2001;
Koller et al. 1990; Kuopio et al. 1999; Morano
et al. 1994; Rocca et al. 1996; Wong et al.
1991) or residence on a farm (Butterﬁeld et al.
1993; Gorell et al. 1998; Semchuk et al. 1991).
Residence in rural locations was found to
be associated with PD in a number of studies
(Butterﬁeld et al. 1993; Golbe et al. 1990; Ho
et al. 1989; Koller et al. 1990; McCann et al.
1998; Morano et al. 1994; Rajput et al. 1986;
Stern et al. 1991; Wong et al. 1991). Yet no
association was found in a few other studies
(Baldi et al. 2003b; Behari et al. 2001; Chan
et al. 1998; Semchuk et al. 1991) and
decreased risk was reported in others (Tanner
et al. 1989; Wang et al. 1993).
Also related to rural or farm living is the
use of well water, possibly associated with
Brown et al.
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contaminants. A number of studies show a
positive association (Koller et al. 1990; Morano
et al. 1994; Rajput et al. 1986; Smargiassi et al.
1998; Wong et al. 1991). However, many oth-
ers found no association for drinking well water
and the development of PD (Behari et al. 2001;
Chan et al. 1998; Engel et al. 2001; Gorell
et al. 1998; Kuopio et al. 1999; Liou et al.
1997; Semchuk et al. 1991; Stern et al. 1991;
Wang et al. 1993), and one found an inverse
relationship (McCann et al. 1998), although
many of these studies may have low power to
detect outcomes, and the study designs vary.
The association between PD and exposure
to metals has been intensely investigated.
Welders exposed to multiple types of metals
appear to be at increased risk of developing
PD, particularly at an earlier age (Racette
et al. 2001). One study showed a subjective
association with increased frequency of heavy
metal exposure; however, this could not be
conﬁrmed (Seidler et al. 1996). Other studies
showed no association for occupational expo-
sures to heavy metals in general (Gorell et al.
1999; Liou et al. 1997).
Results of epidemiologic studies examining
exposure to speciﬁc metals have similarly been
variable. Some studies showed a significant
association with exposure to manganese alone
(Engel et al. 2001; Gorell et al. 1997, 1998,
1999), and Powers et al. (2003) showed a joint
effect with exposure to both manganese and
iron, but others have not found any association
between PD and manganese (Semchuk et al.
1993). This is supported by evidence showing
no change in brain concentration of manganese
(Dexter et al. 1989, 1991, 1992) in PD cases
versus controls. No association was observed for
exposure to iron alone (Gorell et al. 1998) but
was observed for the combination of iron and
copper (Gorell et al. 1997, 1998, 1999), iron
and lead (Gorell et al. 1997, 1998, 1999), and
iron and manganese (Powers et al. 2003).
There is evidence, however, that iron (Dexter
et al. 1989, 1991, 1992; Hirsch et al. 1991;
Riederer et al. 1989; Soﬁc et al. 1988) or fer-
ritin (Dexter et al. 1990) deposits to greater or
lesser degrees in areas of the brain. Exposure to
copper was found to be associated with PD
(Gorell et al. 1997, 1998, 1999; Wechsler et al.
1991), although biomonitoring studies are vari-
able, with some showing an increase (Dexter
et al. 1989, 1992) and another showing no
change in brain concentration (Riederer et al.
1989). Exposure to Al was found to be higher
in male cases than in male controls in one study
(Wechsler et al. 1991) but not in another
(Semchuk et al. 1993). For mercury, one study
found that a signiﬁcantly larger number of PD
cases had dental amalgams than did controls
(Seidler et al. 1996), and an association was
observed between the concentration of mercury
in the blood and urine and PD (Ngim and
Devathasan, 1989), but others showed no asso-
ciation with exposure to mercury (Gorell et al.
1998; Semchuk et al. 1993). Finally, although
zinc was found in the brain tissue of patients
with PD (Dexter et al. 1989, 1991, 1992), no
association for zinc exposure and PD was
observed in another study (Gorell et al. 1998).
Limited epidemiologic studies suggest an
association between exposure to solvents and
PD. One study examined exposure to organic
solvents and found a statistically significant
relationship to the development of PD
(Smargiassi et al. 1998). In addition to the pos-
sibility of solvents causing PD, Pezzoli et al.
(2000, 2004) found that exposure to hydrocar-
bon solvents increased PD severity and earlier
age at onset; another showed suggestive evi-
dence of an association between solvents and
PD (Seidler et al. 1996).
There are claims of an increase of PD for
those working with wood or in other forms of
construction. One study found a nonsignifi-
cant but highly elevated occupational risk
(Hertzman et al. 1990); another found a link
to exposure to wood preservatives (Seidler
et al. 1996); and a third found an increased
risk for those having worked on construction
sites (Herishanu et al. 2001). However, the
agent associated with PD is not determined
for this exposure.
Parkinsonian Syndromes
There are other neurodegenerative conditions
with symptoms similar to PD, including MSA
and PSP. These diseases often can be confused
with PD because they have similar symptoms
and may also co-exist (Drayer et al. 1986).
Therefore, it is important to consider whether
they have similar or distinct etiologies com-
pared with PD and other neurodegenerative
diseases.
MSA is a cluster of three related disorders,
one of which is parkinsonian that is character-
ized by low blood pressure resulting in dizzy
spells. The incidence rate is about 0.6 in
100,000 per year, with the incidence rate
increasing to 3 in 100,000 in the population
older than 50 years (Bower et al. 1997;
Wenning et al. 2004). The evidence of an asso-
ciation with environmental agents is limited.
Nee et al. (1991) found MSA to be signifi-
cantly associated with metal dusts and fumes,
plastic monomers and additives, organic sol-
vents, and pesticides when compared with con-
trols. Case–control studies of biomarkers of
exposure show increased concentrations of iron
in the brains of patients with MSA (Dexter
et al. 1991, 1992) and in patients diagnosed
with both PD and MSA (Drayer et al. 1986)
versus controls. No change in brain concentra-
tion of manganese was observed (Dexter et al.
1991, 1992).
PSP is a neurologic condition affecting the
brainstem that also has symptoms similar to
those of PD. It is characterized by movement
and visual abnormalities. Little is known about
the incidence rate (Bower et al. 1997) or etiol-
ogy of PSP (Davis et al. 1988; Golbe et al.
1996; Pezzoli et al. 2004; Rajput and Rajput
2001; Rehman 2000). Case–control studies
examining the body burden of exposure shows
iron was increased in the brains of patients with
PD (Dexter et al. 1991, 1992) and patients
with both PD and PSP (Drayer et al. 1986).
However, neither iron nor Al in the brains of
cases was found to be different from cases in
another study (Hirsch et al. 1991). Copper was
decreased in the brains of patients with PD
(Dexter et al. 1991, 1992) and manganese had
no effect (Dexter et al. 1991, 1992).
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known
as motor neuron disease or Lou Gehrig’s dis-
ease, is a rare neuromuscular disease with an
incidence rate of about 1 in 100,000. It is char-
acterized by muscular weakness from the
degeneration of motor neurons, and like PD,
intellect and personality is often unaffected.
The National Institute of Neurological
Disorders and Stroke reports that only 5–10%
of all ALS cases can be traced to genetics, par-
ticularly to a mutation related to the superoxide
dismutase 1 enzyme. This leaves the vast major-
ity of cases without a known etiology, with the
potential for environmental association brieﬂy
outlined below.
Far fewer studies have examined the associ-
ation of pesticides and ALS than for both AD
and PD. McGuire et al. (1997) found that
agricultural chemicals have a signiﬁcant associ-
ation with the development in ALS, with a
stronger association for men than for women.
Metals may play a role in the development
of ALS. Some studies have observed an associa-
tion with occupation in welding or soldering
(Armon et al. 1991; Gunnarsson et al. 1992),
but not all have found metals to be related to
ALS (Gresham et al. 1986; McGuire et al.
1997). More specifically, an association has
been observed with exposure to lead (Armon
et al. 1991; Chancellor et al. 1993; Felmus
et al. 1976; Kamel et al. 2002), but no associa-
tion was observed between ALS and lead levels
in various tissues (Kapaki et al. 1989; Stober
et al. 1983) or toenails (Bergomi et al. 2002);
however, these studies had limited numbers
of study participants. No association was
observed between exposure to zinc and ALS
(Vinceti et al. 2002), and the evidence from
biomarker studies is inconclusive, with an
increased (Gellein et al. 2003), decreased
(Yasui et al. 1993), and no association observed
for levels in brain tissue (Kapaki et al. 1997;
Nagata et al. 1985) or toenails (Bergomi et al.
2002) compared with controls. However, these
studies may have had limited power based on
the size of the study population. Although one
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between exposure to copper and ALS (Vinceti
et al. 2002), there was decreased copper con-
centration observed in both cerebrospinal ﬂuid
and blood (Kapaki et al. 1997), and no associa-
tion in toenails (Bergomi et al. 2002) among
patients with ALS versus controls. Mercury
was associated with ALS risk (Felmus et al.
1976) but was found in lower concentrations
in the blood of ALS patients versus controls
(Moriwaka et al. 1993).
Case–control studies examining biomarkers
of iron, manganese, selenium, and Al and risk
of ALS were found. Increased iron levels have
been observed in brain tissue (Kasarskis et al.
1995; Yasui et al. 1993), although not in blood
(Nagata et al. 1985) or toenails (Bergomi et al.
2002). An increase of manganese was observed
in cervical cords (Miyata et al. 1983), both an
increase (Kapaki et al. 1997) and decrease
(Nagata et al. 1985) in blood levels, and no dif-
ference in toenail concentration (Bergomi et al.
2002) among cases versus controls. Selenium
was found to be increased (Nagata et al. 1985)
and decreased (Moriwaka et al. 1993) in blood
cells, but no association was observed in toe-
nails (Bergomi et al. 2002) of patients with ALS
versus controls. An increase was observed in Al
in central nervous system tissue (Yasui et al.
1991a, 1991b) and cerebrospinal ﬂuid (Sood
et al. 1990), yet others observed no association
in spinal cords (Kasarskis et al. 1995) or toe-
nails (Bergomi et al. 2002). However, the latter
two studies had small numbers of study partici-
pants, possibly limiting the power to detect
an association.
A few studies found a relationship between
other exposures and ALS. Gunnarsson et al.
(1992) found a nonsigniﬁcant association with
solvents, but the association was stronger and
statistically significant for males with family
history of neurodegenerative disease or thyroid
disease. Others found conflicting results
(Chancellor et al. 1993; McGuire et al. 1997).
One study found that those with a history of
occupation in the manufacturing of plastics
have a signiﬁcant association with the develop-
ment of ALS (Deapen and Henderson et al.
1986). Occupations in electrical work have
been implicated in the development of ALS in
a few studies (Deapen and Henderson 1986;
Gunnarsson et al. 1992).
Conclusion
Epidemiologic evidence for an association
between environmental agents and neurode-
generative disease is inconclusive. The amounts
of xenobiotics released into the environment
are huge by any measure, and the paucity of
information about their effects on various
physiologic systems, including neurodevelop-
mental processes, represents a major gap in
knowledge. To close this gap, the following
broad areas of research topics need attention:
a) better health tracking and monitoring data
for chronic diseases, b) more comprehensive
and longitudinal biomonitoring of environ-
mental agents that can be linked with speciﬁc
molecular/biochemical markers of exposure
and subsequent health outcome data, and
c) more epidemiologic research and testing of
environmental agents to better define their
effects on the adult and developing brain, as
well as other critical organ systems.
Until such time that ethically and scientif-
ically well-designed epidemiologic studies can
provide a reasonable certainty that specific
environmental agents, either alone or in com-
bination with other agents, cause a given
neurodegenerative disease, research on the envi-
ronmental contribution to neurodegenerative
disease needs to continue.
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